RNAC logo

Cartesian Therapeutics, Inc.

RNAC
Healthcare|Biotechnology|US
$7.53
+0.75 (+11.06%)
DCF Value
$3.97
Cash / Share
$4.06
Next Earnings Report
Mar 8, 2027
EPS est. -$1.14 · Revenue est. $324.4K
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (4)

Dec 2026
Est. completion
P2Systemic Lupus Erythematosus (SLE)
Descartes-08 for Patients With Systemic Lupus Erythematosus
NCT06038474n=6
Dec 2026
Est. completion
P3Myasthaenia Gravis
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247n=128
Nov 2027
Est. completion
P2Antisynthetase Syndrome
Descartes-08 in Autoantibody Myositis
NCT07391605n=60
Dec 2027
Est. completion
P1P2Childhood-onset Systemic Lupus Erythematous
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121n=50

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jan 2026
P2
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051

Recent Press Releases

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026 · GlobeNewsWire
Cartesian Therapeutics Announces New Employment Inducement Grant
Nov 3, 2026 · GlobeNewsWire
Cartesian Therapeutics Announces New Employment Inducement Grants
Oct 2, 2026 · GlobeNewsWire
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Sep 29, 2026 · GlobeNewsWire
Cartesian Therapeutics Announces New Employment Inducement Grants
Sep 8, 2026 · GlobeNewsWire
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Sep 3, 2026 · GlobeNewsWire

SEC Filings (67)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Sep 29, 20268-KMaterial eventDocumentIndex
Aug 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 22, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 17, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 30, 2026S-8Employee stock planDocumentIndex
Apr 30, 202610-QQuarterly reportDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 2, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Dec 18, 20258-KMaterial eventDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Nov 5, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 30, 20258-KMaterial eventDocumentIndex
Oct 21, 20258-KMaterial eventDocumentIndex
Oct 8, 20258-KMaterial eventDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Jun 16, 20258-KMaterial eventDocumentIndex
May 30, 20258-KMaterial eventDocumentIndex
May 8, 2025S-8Employee stock planDocumentIndex
May 8, 202510-QQuarterly reportDocumentIndex
May 8, 20258-KMaterial eventDocumentIndex
Apr 29, 20258-KMaterial eventDocumentIndex